Intelligence · Clinical Development
Pipeline search results
Programs matching “normal” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 28 pipeline programs matching "normal" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
20190531
Amgen
Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).
1 trial -
APHP191047
Pari Pharma GmbH
Patients with microcirculatory abnormalities during septic shock
1 trial -
AUTOP 2
ISTA Pharma Limited
Bacterial vaginosis, High risk preterm birth pregnancy, Vaginal flora abnormalities
1 trial -
Newnorm
Maze Therapeutics
Human Normal Immunoglobulin
1 trial -
Normal Saline
The First People's Hospital of Lianyungang
Postoperative Sleep Disturbance
1 trial -
CAAA617A12202
Novartis Pharmaceuticals
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
1 trial -
CHRMS19-0129
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Use Disorder
1 trial -
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
The George Institute
Colon cancer
1 trial -
bilateral permanent occlusion of uterine arteries
Universal Integrated
Other Abnormal Uterine and Vaginal Bleeding
1 trial -
EDP-788
ENANTA PHARMACEUTICALS INC
Safety in Normal Volunteers
1 trial -
ITF2357-60
Italfarmaco S.p.A.
Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI
1 trial -
J3L-MC-EZEH
Eli Lilly Co.
Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment
1 trial -
J3R-MC-YDAH
Eli Lilly Co.
Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
1 trial -
Lofexidine (granules for reconstitution)
BRIGHT MINDS BIOSCIENCES INC.
Normal Healthy Volunteers
1 trial -
Lofexidine hydrochloride
BRIGHT MINDS BIOSCIENCES INC.
Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product
1 trial -
Lofexidine hydrochloride
BRIGHT MINDS BIOSCIENCES INC.
Normal Healthy Volunteers
1 trial -
Normal Saline (NS) .9% 10 mL Injection
Blackmores Limited
Ovarian Failure
1 trial -
Replens and coconut oil
Summit Therapeutics
Genitourinary Abnormality
1 trial -
Volanesorsen
IONIS PHARMACEUTICALS INC
Abnormalities, Cardiovascular
1 trial -
mHealth application (custom)
BRIGHT MINDS BIOSCIENCES INC.
Cognitive Function Abnormal
1 trial -
mitoxantrone hydrochloride
Karyopharm Therapeutics Inc
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
1 trial -
APHP180618
Pari Pharma GmbH
Asymptomatic Patients with frequent PVCs and normal LVEF
1 trial -
Normal Saline
Nanjing Zenshine Pharmaceuticals
Breast Feeding
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.